Open AccessDendritic cell vaccination in glioblastoma after fluorescence-guided resection
Author(s) -
Ricardo Díez Valle,
Ascensión LópezDíaz de Cerio,
Susana Inogès,
Sonia Tejada,
Fernando Pastor,
Helena Villanueva,
Jaime Gallego,
Jaime Espinós,
Javier Aristu,
Miguel A. Idoate,
Enrique J. Andreu,
Maurizio Bendandi
Publication year - 2012
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v3.i11.142
Subject(s) - medicine , temozolomide , immunotherapy , discontinuation , bevacizumab , chemotherapy , vaccination , oncology , surgery , active immunotherapy , glioblastoma , cancer , immunology , cancer research
To assess whether the addition of a customized, active immunotherapy to standard of care including fluorescence-guided surgery, may provide hints of an improved survival for patients with poor-prognosis, incurable glioblastoma multiform.